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Crystal structure and function of a DARPin neutralizing inhibitor
of lactococcal phage TP901-1: comparison of DARPin and
camelid VHH binding mode
Abstract
Combinatorial libraries of designed ankyrin repeat proteins (DARPins) have been proven to be a
valuable source of specific binding proteins, as they can be expressed at very high levels and are very
stable. We report here the selection of DARPins directed against a macromolecular multiprotein
complex, the baseplate BppUxBppL complex of the lactococcal phage TP901-1. Using ribosome
display, we selected several DARPins that bound specifically to the tip of the receptor-binding protein
(RBP, the BppL trimer). The three selected DARPins display high specificity and affinity in the low
nanomolar range and bind with a stoichiometry of one DARPin per BppL trimer. The crystal structure
of a DARPin complexed with the RBP was solved at 2.1 A resolution. The DARPinxRBP interface is of
the concave (DARPin)-convex (RBP) type, typical of other DARPin protein complexes and different
from what is observed with a camelid VHH domain, which penetrates the phage p2 RBP inter-monomer
interface. Finally, phage infection assays demonstrated that TP901-1 infection of Lactococcus lactis
cells was inhibited by each of the three selected DARPins. This study provides proof of concept for the
possible use of DARPins to circumvent viral infection. It also provides support for the use of DARPins
in co-crystallization, due to their rigidity and their ability to provide multiple crystal contacts.
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Combinatorial libraries of Designed
Ankyrin Repeat Proteins (DARPins) have
been proven to be a valuable source of
specific binding proteins, as they can be
expressed at very high levels and are very
stable. We report here the selection of
DARPins directed against a macromolecular
multi-protein complex, the baseplate BppU-
BppL complex of the lactococcal phage
TP901-1. Using ribosome display we selected
several DARPins that bound specifically to
the tip of the Receptor Binding Protein (RBP,
the BppL trimer). The three selected
DARPins display high specificity and affinity,
in the low nanomolar range, and bind with a
stoichiometry of one DARPin per BppL
trimer. The crystal structure of a DARPin
complexed with the RBP was solved at 2.1 Å
resolution. The DARPin/RBP interface is of
the concave (DARPin) – convex (RBP) type,
typical of other DARPin protein complexes,
and different from what is observed with a
camelid VHH domain, which penetrates the
phage p2 RBP inter-monomer interface.
Finally, phage infection assays demonstrated
that TP901-1 infection of Lactococcus lactis
cells was inhibited by each of the three
selected DARPins. This study provides proof
of concept for the possible use of DARPins to
circumvent viral infection. It also provides
support for the use of DARPins in co-
crystallization, due to their rigidity and their
ability to provide multiple crystal contacts.
Lactococcus lactis is a Gram-positive
bacterium widely used by the dairy industry for
the production of an array of fermented milk
products. Several industrial strains are sensitive
to various distinct bacteriophages, mostly
belonging to the Siphoviridae family. The
lactococcal phage population is divided in at
least ten genetically distinct groups, of which the
936, c2 and P335 groups are prominent (1,2).
These L. lactis infecting phages are considerably
problematic in causing milk fermentation
failures and resulting in decreased yields as well
as low quality products (3). Preventing these
infections has proven to be difficult because of
lactococcal phage ubiquity, biodiversity, and
genomic plasticity (4).
Phage infection is initiated by binding of
the phage Receptor Binding Protein (RBP),
located within the baseplate at the distal part of
the tail, to its receptor on the host cell surface
(5). We have previously solved the crystal
structures of the three RBPs of the lactococcal
phages p2 (936) (6), bIL170 (936) (7), TP901-1
(P335) (8) and their chimera (9) as well as
characterized their saccharide binding sites (10).
The RBPs of these phages have a similar
homotrimeric architecture related by a 3-fold
axis. They comprise three domains: the N-
terminus shoulder domain, the interlaced β-
prism neck domain and the jelly-roll head
domain at the C-terminus. The head domain has
a saccharide binding site likely involved in host
recognition. The lactococcal phage TP901-1
contains a double-disk-shaped baseplate at the
tip of its tail, which is made of a lower baseplate
protein (BppL) and an upper baseplate protein
(BppU) (11).
One strategy to minimize bacteriophage
infections is to competitively block phage
adsorption by adding a protein that specifically
binds to the phage RBP. A neutralizing llama
 http://www.jbc.org/cgi/doi/10.1074/jbc.M109.037812The latest version is at 
JBC Papers in Press. Published on September 9, 2009 as Manuscript M109.037812
 Copyright 2009 by The American Society for Biochemistry and Molecular Biology, Inc.
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 5, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
2VHH domain, recognizing the head domain of
the phage p2 RBP, has been used to block L.
lactis phage infection in milk fermentation (12).
Lactococcal phages could readily escape
neutralization by generating mutations
interfering with VHH binding over the large
interaction surface, while keeping the central
polysaccharide receptor binding pocket intact
(10). Designed Ankyrin Repeat Proteins
(DARPins) may be another tool to neutralize
viral infection since they display distinct
characteristics from VHHs and contain the
required properties in terms of stability and
facility of expression (13).
Ankyrin repeat proteins are found in
virtually all phyla and mediate specific protein-
protein interactions in all cell compartments
(14). The ankyrin elementary module is
comprised of 33 amino acids structured as a β-
turn, followed by two antiparallel α-helices and
a loop connected to the β-turn of the next repeat.
The repeats are stacked in a rigid manner. In
creating a DARPin library, residues in each
repeat were subdivided in two groups: (i)
randomized residues constituting potential target
interaction points; and (ii) framework residues,
important for maintaining the ankyrin fold (13).
Libraries with varying repeat numbers were
assembled and named according to the
constituent repeat number: N2C and N3C
libraries were used in this study, with two and
three internal repeats inserted between the N and
C capping repeats, respectively. DARPins are a
powerful alternative to the use of antibodies,
notably because of their very high expression
rates in E. coli, their high stability paired with
high affinity, and successful reports of their use
in co-crystallization (15-19). Their architecture
results in a very rigid structure that facilitates
multiple crystal contacts, and may promote
crystal formation of the protein of interest by
providing additional surfaces for such crystal
contacts.
We report here the selection and analysis
of DARPin binders directed against a
macromolecular multi-protein ensemble, the
TP901-1 baseplate BppU-BppL protein
complex. Ribosome display selection, ELISA
screening and Surface Plasmon Resonance
(SPR) measurements allowed us to isolate and
characterize three N2C DARPins that recognized
the RBP (BppL of the BppU-BppL complex)
with high specificity and affinity. Further studies
showed that the three DARPins bound to a
unique area of the RBP, at the tip of the head
domain. QELS, MALS, UV and refractometry
coupled, in line, with a size exclusion
chromatography (SEC) column allowed us to
monitor complex formation in solution as well as
to estimate DARPin binding stoichiometry.
Crystals of one of these selected DARPins in
complex with the RBP were obtained and the X-
ray structure was solved at 2.1 Å resolution. This
constitutes the first structure of a DARPin
complex originating from the N2C library, and
the highest resolution for a DARPin complex
structure reported to date. Finally, phage
adsorption inhibition experiments demonstrated
that the three N2C DARPins strongly inhibited
L. lactis infection by TP901-1. We describe the
DARPin/RBP interface and compare it to other
DARPin interfaces. We also compare it to the p2
RBP/VHH5 complex, a previously selected
llama VHH domain inhibiting p2 phage
adsorption (12), to highlight the different
binding mode of these two types of binders.
EXPERIMENTAL PROCEDURES
Target protein preparation. BppU and BppL
coding sequences from phage TP901-1 were
amplified, cloned into a bicistronic operon, and
expressed and purified as described elswhere
(Campanacci et al., Protein science., in
preparation), leading to two distinct fractions:
the BppU-BppL complex and an excess of free
BppL. The BppU coding sequence alone was
also amplified, cloned and expressed as
described elswhere (Campanacci et al., Protein
science., in preparation). The BppU-BppL
complex was biotinylated using Sulfo-NHS-SS-
Biotin (Pierce). First, the protein buffer was
exchanged to 50 mM K2HPO4/KH2PO4 pH 7.8
(4°C), 100 mM NaCl with the aid of a NAP5
column (GE Healthcare). The biotin reagent was
mixed with the protein in a 40:1 molar ratio and
incubated for 4 h on ice. The protein buffer was
then exchanged to a TBS buffer using a NAP5
column and extensive dialysis. The resulting
complex is termed (BppU-BppL)biot.
Ribosome display. Both N2C and N3C DARPin
libraries (13) were used to select for proteins
binding to the BppU-BppL complex using 3
rounds of ribosome display on plates coated
alternately with neutravidin or streptavidin
(20,21). Decreasing coating concentrations of
(BppU-BppL)biot were used in successive rounds:
68, 20 and 10 nM, respectively. The DARPin
libraries were incubated with the target for 1 h at
4°C. Six washes were performed at each round
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3with a buffer containing 50 mM Tris–acetate pH
7.6 (4°C), 100 mM NaCl, 50 mM Mg2+–acetate
and 0.05% Tween-20. Total wash times were
increased from 6 to 45 to 60 min in successive
rounds. At the third round, the translation mix,
c o n t a i n i n g  t h e  t e r n a r y
mRNA–ribosome–DARPin complexes, was first
pre-panned for 30 min at 4°C in one identical
well without the biotinylated target. After
washing, mRNAs were eluted twice with 100 µL
of elution buffer (50 mM Tris–acetate pH 7.6
(4°C), 100 mM NaCl, 25 mM EDTA). The
number of PCR cycles after reverse transcription
was reduced in successive rounds from 40 to 30
to 25, adjusting to the yield due to progressive
enrichment of binders in each round.
Binders identification. MaxiSorp plates (Nunc)
were coated at 4°C overnight with 100 µL of 66
nM NeutrAvidin in TBS, blocked with TBSTB
for 1 h at room temperature (RT) and 100 µL of
(BppU-BppL)biot was added at a final
concentration of 10 nM. Single clones from each
of the two DARPin libraries (N2C and N3C)
were screened by crude extract ELISA as
previously described (22). A 5 µL volume of cell
lysate was mixed with 95 µL TBSTB and added
directly to the target-containing wells, or to a
control well without immobilized target, and
incubated for 1 h at 4°C with orbital shaking.
After washing with TBST, the primary anti-
RGS(H)4 antibody (Qiagen Cat. No. 34650,
1:2000 dilution in TBSTB) was added and
incubated for one hour at 4°C. The wells were
washed with TBST and the secondary goat-anti-
mouse-IgG-AP-conjugate antibody (Pierce Cat.
No. A3562, 1:10000 dilution in TBSTB) was
added. Binding was detected using 3 mM of di-
sodium 4-nitrophenyl phosphate (4NPP, Fluka)
in a buffer containing 50 mM NaHCO3 and 50
mM MgCl2. Absorbance at 430 nm was
measured using a Genios plus plate reader
(Tecan) after 12 h of incubation at RT. We used
a competition ELISA setup to confirm that the
binding of the three selected DARPins to
immobilized (BppU-BppL)biot could be inhibited
by the free BppU-BppL complex in solution.
The protocol was the same as for the crude
extract ELISA, except that crude extracts were
replaced by 100 µL of 150 nM purified
DARPins. In addition, before adding individual
DARPins into each (BppU-BppL)biot-coated
well, the appropriate DARPin was incubated for
1 h at 4°C with several concentrations of free
non-biotinylated target.
DARPins purification and complex preparation.
Enriched DARPins from the N2C and N3C
libraries were cloned into pDST067, a modified
version of the pQE30 vector (Qiagen) (22). This
vector introduced a MRGS(H)6 tag at the N-
terminus. DARPins were expressed in E. coli
XL1-Blue grown in 2xYT medium. Cells were
grown to an OD600 of 0.4 and DARPin
expression was induced with 0.5 mM IPTG for 4
h at 37°C. Cells were resuspended in lysis buffer
(50 mM Tris pH 8.0, 300 mM NaCl, 10 mM
imidazole, 1 mM EDTA, 0.5 mg/ml lysozyme, 1
mM phenylmethylsulfonyl fluoride (PMSF) and
protease inhibitor cocktail (Complete EDTA-
free antiproteases, Roche)), and stored at -80°C.
After thawing, DNAse I and MgSO4 were added
to final concentrations of 10 µg/mL and 20 mM,
respectively. Cells were lysed by sonication and
centrifuged at 20000×g for 30 min. Purification
was performed on an Äkta system using a Ni2+
column (HisTrap Ni2+ 5 mL, GE Healthcare).
Pure proteins were mixed in a 5:1
DARPin/BppU-BppL or DARPin/BppL molar
ratio and incubated for 1 h at RT. The complexes
were purified by a SEC step using a Superose 6
16/60 or a Sephacryl S100 26/60 column (GE
Healthcare), respectively, and run in a buffer
containing 10 mM Hepes pH 7.5, 150 mM NaCl.
Purified complexes were then concentrated up to
5-7 mg/mL with an Amicon Ultra centrifugal
filter device with a molecular weight cutoff of
30 kDa (Millipore). For BIAcore and phage
adsorption inhibition experiments, the three
selected DARPins were each further purified by
a SEC polishing step using a Sephacryl S100
26/60 column, and run in the same buffer as for
complex purification.
SPR measurements. Measurements were
performed in 10 mM Hepes pH 7.5, 150 mM
NaCl, 3 mM EDTA, 0.005% detergent P-20 at
20°C using a BIAcore X100 (BIAcore). We first
coated a CM5 chip (BIAcore) with 100 RU of
one of the three selected DARPins. We also used
the inverse set-up, coating a CM5 chip with
either 200 RU of BppL or 1000 RU of BppU-
BppL. The signal from an uncoated reference
cell as well as the buffer response was subtracted
from all measurements. Initial binding assays
were performed with the BppU-BppL complex,
BppU alone and BppL alone to estimate
specificity, kinetic parameters and/or affinities
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4as well as to map DARPin binding epitopes.
Final measurements were performed using
Single Cycle Kinetic assays to precisely
characterize the binding of each of the three
DARPins at 10, 5, 2.5, 1.25 and 0.625 nM
concentrations (analytes) to either the BppU-
BppL complex or BppL alone (ligand). The KD,
kon and koff values were obtained using the fitting
tool of the BIAevaluation software (BIAcore). A
1:1 binding model was assumed in all cases.
Stoichiometry measurements. We characterized
the mass of each DARPin/target complex using a
combination of UV spectrophotometry, MALS,
and refractometry, coupled in line with an
analytical SEC column. For DARPin/BppU-
BppL complexes, we also determined
hydrodynamic radii using an in line QELS. UV,
MALS, QELS and refractometry measurements
were achieved with a Photo Diode Array 2996
(Waters), a MiniDawn Treos (Wyatt
technology), a DynaPro (Wyatt technology) and
an Optilab rEX (Wyatt technology), respectively
(23). We used either a 24 mL Superose 6 10/30
column (GE Healthcare) run at 0.35 mL·min-1 or
a 15 mL KW-804 column (Shodex) run at 0.5
mL·min-1 on an Alliance HPLC 2695 system
(Waters). The buffer was 10 mM Hepes pH 7.5,
150 mM NaCl, 0.02% NaN3. We injected either
100 µL (Superose 6) or 30 µL (KW-804) of each
complex sample at concentrations of 5 to 7
mg/mL.
Crystallization. We used 5 mg/mL DARPin-
20/BppL complex for crystallization
experiments (the UV extinction coefficient of
the DARPin was not included in the
determination of concentration due to its very
low value). Protein buffer was exchanged by
dialysis to 10 mM Tris pH 7.5, 100 mM NaCl.
An initial hit was obtained in condition 10 of the
Wizard screen (Emerald Biosystem) performed
in 96-well Greiner plates (24,25). This condition
was optimized by varying pH and precipitant
concentration as well as by adding a second
buffer to the crystallization solution. Finally, the
crystal exploited for data collection was grown
within one week from a solution containing 40
mM Tris, 20 mM Bis-Tris-Propane pH 6.0, 25%
PEG 2000 MME. The crystal was cryoprotected
with the mother liquor supplemented with 10%
glycerol and immediately flash-frozen under a
stream of nitrogen.
Data Collection, Structure Determination and
Refinement.  The data set used for structure
determination was collected at beamline ID14-4
(European Synchrotron Radiation Facility,
Grenoble, France). The transmission was set to
20% and each frame was collected with an
exposure time of 1 s and 1° oscillation using an
ADSC Quantum Q315r detector. Ninety images
were integrated and scaled using XDS and
XSCALE (26). The structure was solved by
molecular replacement using AmoRe software
(27) with TP901-1 RBP and H10-2-G3 N2C
DARPin structures as search models (PDB id
2F0C and 2JAB, respectively). Refinement was
carried out using phenix.refine (28) alternating
with manual building in Coot (29). TLS groups
were generated with the TLS Motion
Determination server (30). Data processing and
refinement statistics as well as final model
geometry evaluation are reported in Table 1.
Figures 3 and 4 were generated with Pymol
(http://pymol.org). The coordinates have been
deposited at the Protein Data Bank with the ID
3HG0. The DARPin-20/RBP interface was
analyzed using the Protein Interfaces, Surfaces
and Assemblies (PISA) server (31) as well as
with the protein-protein interaction (ProtorP)
server (32).
Phage inhibition assay. First, Lactococcus lactis
strains were grown at 30°C in M17 broth
(Oxoid) supplemented with 0.5% glucose
(GM17). For phage induction, L. lactis TP901-1
was grown to an OD600 of 0.1 and mitomycin C
was added to a final concentration of 1 µg/ml.
After 20 hours, the clear lysate was filtered
( 0 . 4 5µm) and the phage TP901-1 titer
determined as follows. Ten µl of lysate were
added to 3 ml of GM17 Top Agar (0.75% agar)
containing 300 µL of an overnight culture of L.
lactis 3107 (indicator host strain). The mixture
was then poured onto a GM17 plate (1% agar)
supplemented with 0.5% glycine, incubated
overnight at 30°C, and the plaques were counted.
The protocol for the phage inhibition assay was
adapted from the phage inactivation experiments
described elsewhere (33,34). Approximately 700
plaque-forming unit (pfu) of lactococcal phage
TP901-1 (10 µ l) were mixed with 10 µ l of
DARPin (1, 0.5, 0.1, 0.05, 0.01, 0.005 mg/ml) or
buffer (Hepes 10 mM pH 7.5, NaCl 150 mM).
After an incubation of 1h at 30°C, 20µl of M17
was added to the mixture. Then, the phage titer
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5was determined in triplicate using 10 µl of the
mixture. The percentage of inhibition was
calculated by dividing the phage titer with
DARPin by the phage titer in the buffer (no
DARPin). The quotient was subtracted from 1
and multiplied by 100. The experiment was
repeated three times.
RESULTS
Ribosome display. Ribosome display selections
were performed on (BppU-BppL)biot
immobilized alternately via neutravidin or
streptavidin coated on microtiter plates. Two
DARPin libraries were used for the selection:
N2C and N3C, with theoretical diversities of 5.2
x 1015 and 3.8 x 1023, respectively (13). We
estimated that the initial DNA library diversity
used for ribosome display was about 1012
individual members for each of the two libraries.
We observed a strong enrichment for the N2C
DARPin library after the third round of ribosome
display. The enrichment for the N3C DARPin
library was much less pronounced, probably
since binder enrichment was slower on this
target for this library format. Selected DARPins
from each library were then cloned into the
pDST067 vector (22) to screen single clones.
ELISA screening. Crude extract ELISAs allowed
us to identify three N2C DARPins binding to the
immobilized BppU-BppL complex (Fig. 1A-C)
but no N3C DARPin. The three N2C DARPins
were termed DARPin 18, DARPin 19 and
DARPin 20. After sequence analysis (Fig. 2), the
clones were ranked as independent since many
randomized positions were different for the three
sequences and because they exhibited different
framework mutations (average number of 2,
consistent with previous observations (18)). We
then performed a competition ELISA in which
purified DARPins were pre-incubated with
various concentrations of the free non-
biotinylated target before adding the mixture to
target-coated wells. We clearly observed that the
binding of the three selected DARPins to the
immobilized BppU-BppL complex was inhibited
by addition of the free target, and that this
inhibition was concentration dependent (Fig.
1D-F). This demonstrated that DARPins 18, 19
and 20 bound specifically to the BppU-BppL
complex, since a well coated with only
neutravidin and BSA produced a low signal
compared to target-coated wells, and that they
bind BppU-BppL complex in solution.
SPR kinetic/affinity parameters determination
and epitope mapping studies of DARPin binding.
We measured the kinetic parameters and
calculated the affinity of DARPins 18, 19 and 20
for the BppU-BppL protein complex as well as
for the isolated RBP (BppL trimer) by SPR.
Single Cycle Kinetic experiments yielded very
similar values for kon and koff, and, thus, KD, for
a given DARPin when comparing the binding to
BppU-BppL and BppL. This observation was
true for all three DARPins tested (Table 2).
Affinities of the three DARPins for BppU-BppL
and BppL were in the low nanomolar range, 3.3
to 22 nM for the former and 3.5 to 16 nM for the
latter. These results indicated that the three
selected DARPins recognized only the RBP in
the BppU-BppL complex, despite their sequence
divergence. Moreover, as expected from these
results, no binding was detected for the BppU
protein alone (data not shown). Competition
experiments between the three different
DARPins for binding to BppU-BppL revealed
that each selected DARPin inhibited the binding
of the other two to the target (data not shown).
This led us to conclude that the epitopes of the
three selected DARPins were overlapping or
identical. We thus obtained high affinity (low
nanomolar range) DARPins that recognized the
RBP component of the BppU-BppL complex.
This is the first report of the selection and
characterization of DARPins directed against a
macromolecular multi-protein complex.
Stoichiometry studies of DARPin binding. W e
investigated complex formation and the
stoichiometry on mixing of each of the DARPins
with either BppU-BppL or BppL in solution
using MALS/QELS/UV/refractometry coupled,
in line, with a SEC column (23). Addition of any
DARPin to either target resulted in a shift of the
elution peak to a lower retention volume,
indicating that complex formation had occurred.
Our results also indicated that addition of
DARPins to the BppU-BppL complex resulted in
a 5% increase of the hydrodynamic radii of the
eluted species (Table 3). Finally, we found that
all three DARPins could bind to the BppU-BppL
complex in solution, and that one DARPin could
bind per RBP, independent of whether the RBP
was alone or complexed to BppU (Table 3 A and
B). Thus, complex formation of BppL with
BppU does not influence DARPin binding
stoichiometry. This stoichiometry suggests that
the DARPin binds close to the 3-fold axis to
inhibit the simultaneous binding of other
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6DARPins to the same epitope in the other
subunits.
Structure of the RBP in complex with DARPin
20. An X-ray structure of DARPin 20 bound to
the RBP was solved at a resolution of 2.1 Å (Fig.
3 A and B). This is the first reported structure of
a N2C DARPin complexed with its target. The
overall fold of the RBP is unchanged relative to
the previously reported isolated RBP structure
(8), with r.m.s.d. values for the Cα  atoms
ranging between 0.381 and 0.429 Å for the three
chains relative to the corresponding chain in the
original structure. Nevertheless, a major
difference is visible in the crystal structure
described here: no electron density was observed
before residue 32 (in the best case, chain C)
suggesting that the RBP was proteolyzed and,
thus, lacks the three-helix-bundle domain. Such
a phenomenon was previously observed in the
phage TP901-1 RBP structure lacking the first
16 residues (8), as well as in the phage p2 RBP
structure in complex with VHH5, in which only
the three-β-barrel domain of the RBP was found
in complex with its antibody partner (6).
DARPin 20 binds to the top of the head
domain at a ratio of 1:1 DARPin/RBP, that is in
agreement with the stoichiometry determined in
solution. Crystal contacts are mediated both by
the DARPin and the RBP. In the crystal lattice,
each DARPin interacts with two RBPs in
addition to the target RBP, whereas each RBP
contacts 4 other RBPs and 3 DARPins in
addition to its binding partner. Thus, DARPin 20
contributes extensively to the crystal packing,
bearing out the promise from the extended rigid
scaffold, and underlining its utility in co-
crystallization.
Analysis of the interaction between the RBP and
DARPin 20. DARPin 20 interacts with a convex
surface formed by the three chains of the RBP
via its own concave randomized surface (Fig. 3
C, D and E). However, most of the RBP surface
area buried in the interface is contributed by
chain A, reaching 512 Å2, whereas the value for
the whole RBP is 737.3 Å2. All four DARPin 20
repeats interact with the RBP, i.e., the two
randomized repeats and the two capping repeats
resulting in a buried surface area of 665.6 Å2.
The first α-helix of each of the four repeats as
well as the three β -turns separating the four
repeats carry all the target interacting residues.
The interaction surface of the RBP is formed by
residues located in the loops connecting the
strands of the three β-barrels of the head domain.
The interface between the two partners involves
20 residues from the DARPin and 20 residues
from the RBP, resulting in a total interface
buried surface area of 1402.9 Å2. Residues
involved in the interaction interface are listed in
Table 4. Among the 14 randomized positions of
DARPin 20, 9 are involved in the interface,
illustrating the robustness of the library design.
The 11 remaining residues participating in the
interaction with the RBP are conserved
framework residues. None of the two introduced
framework mutations directly contribute to the
binding interface or influence the overall ankyrin
fold.
The involvement of the three RBP
protomers in forming the DARPin epitope
explains the observed stoichiometry, illustrating
that it would be impossible to bind a second
DARPin to the same RBP. Hydrogen bonds and
Van der Waals contacts mediate the binding of
DARPin 20 to the RBP, and no salt bridge is
observed. Of particular interest is the unusual
hydrogen bond formed between residues Tyr90
of DARPin 20, a selected residue in a
randomized position, and Trp129 of RBP
monomer B. The N-H group of the indole ring
from Trp129 interacts with the π  electronic
cloud of the phenol ring from Tyr90 of DARPin
20 (Fig. 3A, inset). On one side, the Trp129 side
chain is maintained in a defined orientation by a
stacking to residue Asn130 and Van der Waals
contacts to Met 125, both provided by chain A
of the RBP. On the other side, the Trp129 side
chain interacts with residues Trp144 and Pro147
from chain A as well as Met89 from DARPin
20, still via Van der Waals contacts. It should be
noted that the latter residue is also located at a
randomized position and was selected.
The convex-shaped epitope on the RBP
fits perfectly with the concave-shaped paratope
on the DARPin (Fig. 3 C, D and E), which is a
general feature of DARPin interaction and is
reminiscent of all other DARPin/target complex
structures. The main part of the interaction
interface (61% of the DARPin 20 interface
buried surface area) is mediated through residues
in randomized positions, explaining the high
specificity of the selected molecules. In contrast
to most DARPin/target complexes (with the
exception of the AcrB/110818 complex), the C-
terminal capping repeat is fully ordered and
involved in the interaction surface in contacting
RBP chain C. Since the first interacting residue
is at position 20 and the last at position 124, the
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7full width of the 136 amino acid residues of
DARPin 20 is involved in this complex.
Neutralization of phage TP901-1 by DARPins
18, 19 and 20. Finally, the binding of the three
selected DARPins was tested against the whole
phage TP901-1. All three DARPins inhibited, in
a concentration-dependent manner, the infection
of L. lactis cells by lactococcal phage TP901-1
(Table 5). Although all three DARPins were
similarly effective, DARPin 19 was the most
efficient inhibitor while DARPin 20 was the
least reflecting measured affinities. Structural
analysis of the DARPin 20 bound to the RBP
and the interaction site of polysaccharide with
the RBP suggested that the inhibition was
probably due to steric hindrance. Indeed,
DARPin 20 did not directly protrude into the
polysaccharide binding site, but was slightly
more distant. Nevertheless, the observed
inhibition probably resulted from the fact that
DARPin 20 binding to TP901-1 phage precluded
its interaction with polysaccharides located on
the surface of the gram-positive bacterium, thus
preventing the phage from anchoring to its host.
Furthermore, the similar behavior of DARPins
18, 19, and 20 in phage infection inhibition
experiments reinforces our hypothesis that they
share a common epitope on the RBP.
DISCUSSION
When we analyzed the crystal structure
of the DARPin 20/RBP complex, we observed
that most of the DARPin 20-interacting residues
were conserved in DARPins 18 and 19. This
information, along with the results of the SPR
competition experiments and the phage infection
inhibition experiments, allowed us to reasonably
suggest that the three DARPins probably share
identical epitopes on the RBP. Furthermore, the
three selected DARPins exhibited a conserved
Tyr residue at the randomized position 90. Thus,
the N-H---π  interaction between the Tyr90
residue and Trp129 of the RBP chain B seems to
be conserved.
Comparison with previously obtained
DARPins, for which co-crystallization in
complex with a target was successful and led to
structure determination, revealed two interesting
features: (i) the measured binding affinities of
the three selected N2C DARPins for the BppU-
BppL complex or for the isolated RBP fell in the
range of the previously reported ones for N3C
DARPins (35); (ii) the overall buried surface
area of the DARPin 20/RBP interface is also
comparable to previously reported surface areas,
but it is among the smallest (35). This value is
also roughly identical to those reported for
antibody-antigen complexes.
In contrast to DARPin 20, the structure
of the lactococcal phage p2 RBP in complex
with a llama antibody fragment (VHH5)
revealed that VHH5 binds the RBP at the
interface between two β-barrels (Fig. 4). This
implied that three VHH5 proteins are bound to
each RBP, because of its internal molecular
symmetry, in contrast to the unique DARPin 20
interacting with one RBP at the top of the head
domain. Each VHH5, thus, interacts with two
RBP chains, whereas DARPin 20 contacts three
RBP chains. However, the surface area buried in
the interface, is roughly comparable with
DARPin 20: VHH and p2 RBP averaged buried
surface areas are of 699.2 Å2 and 667.2 Å2,
respectively. This yielded a total value of 1366.4
Å2, very similar to the DARPin 20/TP901-1
RBP interface. Furthermore, the reported affinity
of VHH5 for lactococcal phage p2 RBP (1.4
nM) (36) is similar to the measured affinities of
DARPins 18, 19 and 20 for the lactococcal
phage TP901-1 RBP. The protruding paratope of
VHH5 penetrates into a crevice-shaped epitope
located between two RBP protomers. Both
VHH5 and p2 RBP contributes to the interface
with 20 residues each, mediating hydrogen
bonds and Van der Waals contacts, as for the
complex described in this study.
These two RBP-binding molecules
(VHH and DARPins), whose specificities are
illustrated by the two complex structures, rely on
very different scaffolds. VHHs have an
immunoglobulin domain scaffold displaying 3
CDR loops to achieve target binding (37-39). In
contrast, DARPins combine both an extended
flat surface (formed by the first α-helix of each
repeat) and turns to bind their targets. VHH5 and
DARPin 20 employ opposite interaction modes
with their targets, the convex VHH5 interacting
with a concave target structure whereas DARPin
20 displays a concave surface that binds a
convex epitope. DARPin binding mode is more
rare and constitutes an elegant alternative
approach to the antibody binding mode. Since
almost all proteins contain domains that will
present a convex surface, DARPin binding
appears to be of a general nature.
The problems caused by phage
infections in industrial dairy processes were
identified and characterized many years ago (3),
and, ever since, research has been directed at
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8finding ways to circumvent these problems. One
solution proposed was to add a neutralizing
antibody fragment to inhibit the first event of
phage infection: RBP interaction with the host
cell wall. A successful illustration of this
principle was provided by the selection of the
VHH5 antibody, which blocked adsorption of
the p2 phage to its host (12,36).
Given the non-optimized DARPin 20
expression yield in Escherichia coli (185 mg/L
of shake flask culture), it is reasonable to believe
that efforts to optimize this yield for industrial
purposes would easily provide very large
quantities of purified DARPin. The convenience
of DARPin purification, providing pure protein
with a single IMAC step, is of great benefit in
applying such proteins as scalable and robust
industrial tools.
 Before looking at industrial applications
and government’s regulatory process, a number
of additional experiments are needed to support
this proof of concept study. For example, with
regard to the broadness of the protection
provided by the DARPin binders isolated in this
study against other phages of the P335 group,
which is a notoriously diverse group of phages
(40). Moreover, other phage-neutralizing
DARPin binders would have to be developed
against other predominant lactococcal phage
groups (936 and c2), which are genetically
distinct from the P335 group (41). As
lactococcal phages are known to mutate either
by point mutation or recombination when facing
selective pressure (42), it has to be demonstrated
if these phages can easily mutate to circumvent
the inhibition provided by DARPin binders. It is
worth mentioning, as suggested previously (12),
that a mutation in the gene encoding the phage
structural protein recognized by the DARPin
binders may lead to a change in the host range
and may also prevent the adsorption of the
mutated phage to its natural host.
CONCLUSIONS
We report here, for the first time, the
selection of DARPins directed against a hetero-
oligomeric macromolecular multi-protein
complex: the BppU-BppL complex, which
comprises part of the baseplate of the L. lactis-
infecting phage TP901-1. The crystal structure
of one of the selected high-affinity DARPins in
complex with the TP901-1 RBP, determined at
2.1 Å resolution, showed that the concave
DARPin binding site interacts with a convex
surface of the RBP, such that one DARPin binds
one RBP. This stoichiometry is consistent with
measurements in solution. The observed
DARPin binding mode differs significantly from
that of a camelid VHH (VHH5) interacting with
a concave RBP surface (6). DARPins and VHHs
provide two classes of binders with opposite
characteristics, thus allowing a large coverage of
antigens surface. We also demonstrated that the
three selected DARPins inhibited TP901-1
infection. It should be noted that we obtained
low nanomolar DARPins with only three rounds
of ribosome display. Two additional rounds with
error prone PCR and selection for affinity (43)
would probably result in the selection of
picomolar DARPins, further reducing the
required quantity of DARPIN necessary to
phage neutralization. Considering the high
expression yield of DARPin 20 in E. coli, as
well as its low nanomolar affinity for the RBP,
we believe that we have provided a proof of
concept for the use of DARPins to circumvent
phage infection. The use of DARPins as a tool to
fight viral infections in general, including those
affecting humans, might also be considered. .
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FIGURE LEGENDS
Figure 1.
Top: Single clone crude extract ELISAs. (A) DARPin 18, (B) DARPin 19 and (C) DARPin 20.
DARPin binding was tested on a well with neutravidin-immobilized (BppU-BppL)biot and compared to
the signal intensity obtained from a control well with only neutravidin and BSA. Bottom: Competition
ELISAs. DARPins 18 (D), 19 (E) and 20 (F) were pre-incubated with increasing concentrations of free
non-biotinylated BppU-BppL complex for 1h at 4°C before addition to their respective ELISA wells.
Figure 2.
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Sequence alignment of DARPins 18, 19 and 20. The DARPin consensus is displayed with X
indicating randomized positions (any amino acid residues except glycine, proline and cysteine), Z for
the partially randomized positions (allowing histidine, tyrosine or asparagine), all remaining positions
being framework residues (13). This figure was created with Multalin (44).
Figure 3.
Structure of the RBP/DARPin 20 complex. (A) Overall structure with both DARPin (rainbow-colored)
and the RBP (the three chains being colored in salmon, purple and yellow) in cartoon representation.
inset: detail of the interactions involving a central role of Tyr90 from the DARPin; the small letters
refer to DARPin (d) and the a,b,c chains of the RBP. (B) Overall structure of the two partners with
molecular surface representation according to the same color scheme as in A. (C) Interface region with
the buried surface area of the DARPin colored red, green and yellow corresponding to interaction with
chain A, B and C of the RBP, respectively. (D) Same view as in D rotated approximately by 90°. (E)
Illustration of the concave (DARPin) – convex (RBP) type of the interaction interface.
Figure 4.
Comparison of the phage TP901-1 RBP/ DARPin 20 complex with the phage p2 RBP/VHH5 complex
(6). The three VHH5 have been superimposed on the TP901-1 RBP structure for comparison, taking
advantage of the 3D similarity of the two RBPs. The blue grid locates the bound glycerol in the
receptor binding site (10). Each VHH5 binds in a crevice between two subunits. The structure of the
three VHHs was taken from the PDB entry 2BSE.
Table 1. Summary of data collection and refinement statistics.
Data collection
Space group P212121
Cell dimensions (Å) 46.650   80.440  182.870
Resolution (Å) 19.86-2.1 (2.1-2.3)
Completeness 97.1 (91.8)
Redundancy 3.58 (3.67)
I/σ(I) 12.43 (2.48)
Rmerge (%) 6.5 (51.8)
Refinement
Resolution (Å) 19.89-2.1 (2.1-2.3)
Protein/solvent atoms 3933/446
R/Rfree (%) 20.79/24.27
r.m.s. deviations on bonds (Å) / angles (degrees) 0.014/1.676
Table 2. DARPins 18, 19 and 20 affinities and kinetic parameters for BppU-BppL and BppL
determined by SPR (BIAcore).
BppU-BppL / BppL
kon (1/Ms)
BppU-BppL / BppL
koff (1/s)
BppU-BppL / BppL
KD (M)
χ2
DARPin 18 2.63·106 /2.40·106 1.60·10-2 / 1.80·10-2 6.00·10-9 / 7.47·10-9 0.295 / 0.124
DARPin 19 1.40·107 /1.70·107 5.80·10-2 / 5.90·10-2 3.30·10-9 / 3.50·10-9 2.41 / 0.004
DARPin 20 4.10·106 /       - 9.00·10-2 /       - 2.20·10-8 / 1.60·10-8 0.199 / 0.002
Table 3 A. Stoichiometry of BppU-BppL/DARPin complexes.
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A Theoretical
Mw (Da)
Mw measured
by
MALS/refrac
tometry/SEC
(Da)
Stoichiometry
(BppU3-
BppL9):
DARPins
(BppU3-
BppL9)/
DARPin
Rh
QELS (nm)
(BppU3-
BppL9)
263 640
(9·17 970 +
3· 33 970)
255 000 - 6.0
(BppU3-
BppL9)+
DARPin 18
308 025
(263 640 +
3·14 795)
291 000 1:3 6.6
(BppU3-
BppL9)+
DARPin 19
307 971
(263 640 +
3·14 777)
289 000 1:3 6.4
(BppU3-
BppL9)+
DARPin 20
307 788
(263 640 +
3·14 716)
285 000 1:3 6.4
B. Stoichiometry of BppL/DARPin complexes.
B Theoretical
Mw (Da)
Mw measured
by
MALS/refracto
metry/SEC
(Da)
Stoichiometry
BppL3:
DARPins
BppL3 53 910
(3·17 970)
54 000 -
BppL3 +
DARPin 18
53 910 + 14
795)
63 627 1:1
BppL3 +
DARPin 19
53 910 + 14
777)
60370 1:1
BppL3 +
DARPin 20
53 910 + 14
716)
61 618 1:1
Table 4. Residues involved in the interaction interface between DARPin 20 and the RBP.
Chain Residue Chain Residue
D GLU 20 A GLU 93
D ARG 23 A ILE 94
D ASP 44 A SER 95
D VAL 46 A SER 96
D LEU 48 A SER 97
D LEU 53 A LEU 99
D MET 56 A ALA 100
D ASN 57 A ASN 101
D ASP 77 A ASN 130
D ALA 78 A PRO 147
D ILE 79 A THR 148
D GLU 81 A ALA 149
D LEU 86 A SER 150
D MET 89 A SER 151
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D TYR 90 B GLY 127
D PHE 112 B GLY 128
D LYS 114 B TRP 129
D ASP 122 B ASN 130
D ASN 123 B SER 151
D GLY 124 C TRP 129
Table 5. Inhibition of lactococcal phage TP901-1 by DARPins.
DARPin
concentration DARPin 18 DARPin 19 DARPin 20
1 mg/ml 100.0 %  ± 0.0 100.0 % ± 0.0 87.6 % ± 10.8
0.5 mg/ml 99.6 % ± 0.40 100.0 % ± 0.0 75.9%  ± 22.4
0.1 mg/ml 91.2 % ± 7.8 95.8 % ± 1.9 60.7%  ± 17.2
0.05 mg/ml 69.1 % ± 9.0 79.7 % ± 12.1 61.2%  ± 10.6
0.01 mg/ml 13.2 % ± 8.5 31.2 % ± 8.8 23.6%  ± 20.8
0.005 mg/ml 4.5 % ± 7.7 39.0% ± 10.2 5.8%  ± 18.5
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